IP Library Granted Patent US 10,485,850
Granted Patent B2
US 10,485,850 · App. 15/594,998 · Granted Nov 26, 2019

Methods for producing stable therapeutic formulations in aprotic polar solvents

Inventors: Steven Prestrelski (Chicago, IL); Michael Sandoval (Chicago, IL); Martin Donovan (Chicago, IL)
Assignee: XERIS PHARMACEUTICALS, INC.
A61K38/26A61K9/0019A61K9/08A61K38/00A61K47/00A61K47/02A61K47/10A61K47/12A61K47/183A61K47/186A61K47/20A61K47/26A61M5/142A61M5/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,485,850
App. No.
15/594,998
Granted
Nov 26, 2019
Kind
B2
Abstract

Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

Claims (16)

1. A stable formulation comprising:

(a) a therapeutic glatiramer or pramlintide peptide, wherein the peptide is not prepared by drying in the presence of a non-volatile buffer;

(b) an ionization stabilizing excipient, wherein the ionization stabilizing excipient is an acid; and

(c) an aprotic polar solvent;

wherein (i) the therapeutic peptide is dissolved in the aprotic solvent in an amount from about 0.1 mg/mL up to the solubility limit of the therapeutic peptide, and (ii) the ionization stabilizing excipient is dissolved in the aprotic polar solvent in an amount to stabilize the ionization of the therapeutic peptide.

2. The formulation of claim 1 , wherein the ionization stabilizing excipient is at a concentration of 0.1 mM to less than 100 mM.

3. The formulation of claim 1 , wherein the ionization stabilizing excipient is a mineral acid.

4. The formulation of claim 1 , wherein the aprotic polar solvent is dimethyl sulfoxide (DMSO).

5. The formulation of claim 1 , wherein the aprotic polar solvent is a deoxygenated aprotic polar solvent.

6. The formulation of claim 5 , wherein the deoxygenated aprotic polar solvent is deoxygenated DMSO.

7. The formulation of claim 1 , wherein the ionization stabilizing excipient is a mineral acid and the aprotic polar solvent is DMSO.

8. The formulation of claim 1 , wherein the total moisture content is less than 5% w/w.

9. The formulation of claim 1 , further comprising a preservative at less than 10% w/v.

10. The formulation of claim 9 , wherein the preservative is benzyl alcohol.

11. The formulation of claim 1 , further comprising a sugar alcohol at less than 10% w/v.

12. The formulation of claim 11 , wherein the sugar alcohol is mannitol.

Assignments (4)
REASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Mar 10, 2022
From: OXFORD FINANCE LLC
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 059358/0700 →
SECURITY INTEREST Recorded Mar 9, 2022
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LIMITED
To: HAYFIN SERVICES LLP
Reel/Frame 059552/0066 →
SECURITY INTEREST Recorded Sep 12, 2019
From: XERIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050362/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2017
From: PRESTRELSKI, STEVEN; SANDOVAL, MICHAEL; DONOVAN, MARTIN
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 043873/0838 →
Continuity (3)
Continuation 15136650 · Apr 22, 2016
Provisional Application 62233032 · Sep 25, 2015
Related Publication 20170312341A1 · Nov 2, 2017
Cited By (2)
US 12,514,837 US 12,691,089